University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that featured Novo and Boehringer Ingelheim.
HepaRegenix, a Germany-based liver disease medicine spinout of University Hospital Tübingen, completed a series B round yesterday that exceeded €11m ($12.2m) with investors including pharmaceutical firms Boehringer Ingelheim and Novo.
Multi-institute tech transfer company Ascenion, public-private partnership High-Tech Gründerfonds (HTGF) and Coparion, an investment fund backed by the German government and the EU, also took part in the round. Boehringer Ingelheim particiapted through its Venture Fund.
Founded in 2015, HepaRegenix is working on drugs for acute and chronic liver diseases…
